Overview
Stilnox Treatment in Elderly Patients With Insomnia
Status:
Completed
Completed
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
Primary objective: 1. To evaluate the efficacy of Zolpidem 5mg for 1 week in elderly patients with insomnia in China Secondary objectives: 1. To evaluate the safety of Zolpidem 5mg for 3 weeks in elderly patients with insomnia in China. 2. To evaluate the efficacy of Zolpidem 5mg for 3 weeks in elderly patients with insomnia in ChinaPhase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
SanofiTreatments:
Zolpidem
Criteria
Inclusion Criteria:- Primary out-patient insomniac patient defined by DSM-IV criteria
- Insomnia history lasted at least 3 months , this history must include a self-reported
usual sleep latency of 30 minutes or more and either 3 or more awakenings per night on
average or a usual total sleep time of ≤6.5 hours
Exclusion Criteria:
- Usage of hypnotics within the previous 1-3 weeks before inclusion depending on the
half-life of the hypnotics that would affect the study effect
- Concomitant usage of other hypnotics (benzodiazepines and Non-benzodiazepines) during
the course if the study.
- Concomitant usage of the following Central Nervous System active medicine :
antipsychotics , antidepressants ,anxiolytics, lithium and other psychotropic drugs.
- The score of Hamilton Depression Rating Scale (HAMD-24 ) more than 17.
- The score of Hamilton Anxiety Rating Scale (HAMA-14 ) more than 14.
- Patients having known hypersensitivity to Stilnox or any of the ingredients in the
products
- Patient with severe respiratory insufficiency
- Patients suffering from sleep apnoea syndrome
- Patients with known severe hepatic (risk of encephalopathy) and /or renal
insufficiency, or other severe organ diseases
- Patients suffering from severe myasthenia gravis
- Patients with the previous history of drug abuse, drug dependence and drug addiction
- Any other disease state or major psychiatric condition that might affect study result
The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.